Survival of FUS–ERG and CBFA2T3/RUNX1 AML compared with a pediatric AML reference cohort. (A-C) Survival curves of patients with FUS-ERG–rearranged AML and CBFA2T3/RUNX1–rearranged AML compared with the BFM reference cohort. (D-F) The reference cohort is split up according to high and standard risk.